Skip to main content

Table 2 Subgroup analysis

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

Subgroup categoryOR rateCR rateRR
Study, nORR (95% CI)I2 (%)Study, nCRR (95% CI)I2 (%)Study, nRR (95% CI)I2 (%)
Overall370.84 (0.80, 0.88)75.76370.61 (0.49, 0.73)97.46320.21 (0.15, 0.26)75.73
Study design
 Clinical trial130.80 (0.72, 0.89)83.81130.56 (0.32, 0.80)98.54110.15 (0.07, 0.22)73.10
 Observational study240.85 (0.80, 0.89)69.89240.64 (0.51, 0.76)95.79210.23 (0.17, 0.30)72.29
Diagnosis
 AIHA240.79 (0.73, 0.84)73.20240.44 (0.33, 0.55)93.13190.28 (0.20, 0.36)76.36
 wAIHA80.79 (0.69, 0.90)75.8980.49 (0.22, 0.77)96.2770.31 (0.14, 0.47)82.22
 CAD50.66 (0.57, 0.76)45.9950.14 (0.03, 0.25)82.5740.31 (0.10, 0.53)81.81
 MAHA130.93 (0.89, 0.97)46.99130.93 (0.89, 0.97)46.99130.09 (0.05, 0.13)29.13
 TTP120.92 (0.88, 0.96)50.74120.92 (0.88, 0.96)50.74120.08 (0.04, 0.12)21.38
 HUS10.97 (0.88, 1.06) 10.97 (0.88, 1.06) 10.29 (0.05, 0.52) 
Dosage regimen
 375 mg/m2 4 weekly280.83 (0.78, 0.88)78.64280.62 (0.48, 0.77)98.03240.20 (0.14, 0.26)77.50
 Other regimen80.84 (0.76, 0.91)67.4980.56 (0.45, 0.67)70.8070.24 (0.13, 0.32)72.87
Treatment modalities of AIHA
 RTX alone140.82 (0.76, 0.88)72.74140.44 (0.29, 0.59)93.22120.30 (0.20, 0.40)78.27
 In combination100.74 (0.66, 0.81)59.22100.45 (0.27, 0.63)93.7070.26 (0.12, 0.39)76.19